Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Company Deals

Ribo Life Science Acquires Additional 25.93% Stake in Azemidite for RMB 70 Million – Strengthens siRNA Therapeutics Supply Chain

Fineline Cube Jul 1, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Fineline Cube Jul 2, 2026
Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Fineline Cube Jul 2, 2026
Company Drug

VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%

Fineline Cube Aug 8, 2023

Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600%...

Company Legal / IP

Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute

Fineline Cube Aug 8, 2023

A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly &...

Company Drug

BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448

Fineline Cube Aug 8, 2023

China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...

Company

Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth

Fineline Cube Aug 8, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the...

Company Deals

Beijing’s Gene Cradle Secures Pre-Series B+ Funding Led by Cash Capital

Fineline Cube Aug 8, 2023

Gene Cradle, a Beijing-based gene therapy specialist, has reportedly secured tens of millions of renminbi...

Company Deals

Gracell Biotechnologies Secures $100 Million in Private Placement with Healthcare Investors

Fineline Cube Aug 8, 2023

Suzhou-based biotech firm Gracell Biotechnologies Inc., (NASDAQ: GRCL) has announced a purchase agreement with a...

Policy / Regulatory

National Health Commission Unveils 10 Measures to Enhance Primary Healthcare Services

Fineline Cube Aug 8, 2023

The National Health Commission has issued a Notice outlining “Measures for Grassroots Health and Convenient...

Company Drug

Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae

Fineline Cube Aug 7, 2023

Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...

Company Deals

ABVC Biopharma Grants Xinnovation Therapeutics Exclusive Rights to CNS Drug Pipeline in China

Fineline Cube Aug 7, 2023

US-based ABVC Biopharma Inc. has entered into a legally binding term sheet with China-based Xinnovation...

Company Deals

Oramed Pharmaceuticals and Hefei Tianhui Biotech to Form Joint Venture for Oral Insulin Product

Fineline Cube Aug 7, 2023

Israel-based drug developer Oramed Pharmaceuticals Inc., (NASDAQ: ORMP) has revealed that a deal has been...

Company Drug

Astellas Pharma’s Izervay Receives FDA Approval for Geographic Atrophy Treatment

Fineline Cube Aug 7, 2023

Japan-based Astellas Pharma Inc., (TYO: 4503) has announced that it has received new market approval...

Company

Regeneron Pharmaceuticals Halts Enrollment in REGN5678 Clinical Trial After Patient Deaths

Fineline Cube Aug 7, 2023

US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has reported in its Q2 2023 financial results the...

Company Drug

Ascentage Pharma’s Lisaftoclax (APG-2575) Gets FDA Green Light for Phase III Study

Fineline Cube Aug 7, 2023

China-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the US...

Company Medical Device

Jenscare Scientific and Lifetech Scientific Achieve Milestone with First Compassionate Use of LuX-Valve Plus

Fineline Cube Aug 7, 2023

Partners Jenscare Scientific Co., Ltd. (HKG: 9877), a leading structural heart disease device manufacturer based...

Policy / Regulatory

GuangDong Pharmaceutical Association Releases Updated Off-Label Drug List for 2023

Fineline Cube Aug 7, 2023

The GuangDong Pharmaceutical Association has released the 2023 version of its off-label drug list, marking...

Company Medical Device

Venus Medtech Receives FDA IDE Approval for VenusP-Valve, a Milestone for Chinese Heart Valve Technology

Fineline Cube Aug 7, 2023

Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced obtaining Investigational Device Exemption (IDE) approval from...

Company Medical Device

MicroPort CardioFlow Announces Positive Results for Transcatheter Mitral Valve Replacement System

Fineline Cube Aug 7, 2023

China-based MicroPort Scientific Corp’s spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has announced positive...

Company Deals

Hansoh Pharmaceutical Regains Rights to Ameile After EQRx Partnership Cancellation

Fineline Cube Aug 7, 2023

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced the cancellation of its partnership and...

Company Deals

Jumpcan Pharmaceutical Partners with Nanjing Zenshine for Exclusive Promotion Rights of ZX-7101A in China

Fineline Cube Aug 7, 2023

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a strategic partnership with fellow Chinese firm Nanjing...

Company

Gilead Sciences Inc. Reports 5% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 4, 2023

US-based pharmaceutical major Gilead Sciences Inc., (NASDAQ: GILD) has released its financial results for the...

Posts pagination

1 … 515 516 517 … 689

Recent updates

  • Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval
  • Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy
  • Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile
  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
  • Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.